Prediction markets Kalshi and Polymarket estimate a roughly 33-38% chance that Bitcoin will reach $100,000 before the end of 2026. Kalshi's contract shows a 38% probability based on the CF Bitcoin Real-Time Index, while Polymarket's contract indicates a 31% chance using Binance BTC/USDT prices. Bitcoin was trading around $83,477 on Sept. 29, so reaching $100,000 would require about a 20% price increase. These market-based probabilities provide real-time sentiment but are not formal forecasts, and contract rules differ slightly between platforms.
Bitcoin's 2026 price prediction is the subject, with a 33-38% chance of reaching $100,000. For readers following cryptocurrency, here is Pluang's market snapshot as of Sep 29, 2026 18:02 WIB: of 50 major cryptocurrencies, 38 rose and 11 fell. Notable movers include GRT at Rp550 with a -4.64% change and 92% sell order activity, COTI at Rp232 with -4.51% change and 80% buy order activity, and XTZ at Rp5.817 with +4.17% change and 59% buy order activity.
Realty Income, a real estate investment trust, stands out with its monthly dividend payments and a strong history of 136 dividend increases since 1994, currently yielding about 5.9%. This provides investors with a steady income stream, despite the st...
Ethereum's price remained stable around $2,711 with minimal daily fluctuations, while network fees for simple ETH transfers dropped to about six cents due to low gas prices near 1 Gwei. This creates an unusually cheap opportunity for investors to mov...
Zcash developers have integrated the Tachyon project's recursive proof code into their Zakura Common cryptographic stack via the new Udon Rust crate, aiming to dramatically increase shielded transaction speeds. This upgrade targets processing over 50...
Avalanche (AVAX) surged 3.80% within one hour to $11.98 on September 29, extending its 24-hour gain to 14.28%. The price increase was recorded on Binance’s AVAX/USDT spot market. During this period, short-position liquidations across Binance, Bybit, ...
City Therapeutics is preparing for a U.S. IPO to raise funds for its RNAi therapeutic pipeline, including its lead candidate CITY-FXI aimed at treating thrombosis. The company has shown promising early Phase 1 results and benefits from strong partner...
